Breaking News

Lonza, BioWa Ink License Pact with Pfizer

Will use POTELLIGENT CHOK1SV cell line

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioWa, Inc. and Lonza have entered into a research agreement with Pfizer for the use of their POTELLIGENT CHOK1SV cell line in the R&D of multiple antibodies in Pfizer’s pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT technology with Lonza’s GS Gene Expression System, which includes the host cell line, CHOK1SV.   “We are pleased that the core value of POTELLIGENT Technology has been recogniz...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters